Data completeness
2/8 — Basic
EQUANIL (meprobamate) by Thayer Medical is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EQUANIL (meprobamate) is an oral carbamate derivative anxiolytic indicated for short-term relief of anxiety symptoms. It works by suppressing activity in the thalamus and limbic system regions of the central nervous system. The product is in pre-launch stage under sponsor Thayer Medical.
Pre-Launch
Pre-launch stage indicates early-stage team building with growth potential if regulatory approval is achieved; limited commercial data available.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on EQUANIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.